Search

Displaying results 1901 - 1910 of 10000 in total
  1. Drug

    Semaglutide

    go.drugbank.com/drugs/DB13928
    ApprovedInvestigational

    Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. … The use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective.

  2. Drug

    Dicloxacillin

    go.drugbank.com/drugs/DB00485
    ApprovedInvestigationalVet approved

    One of the penicillins which is resistant to penicillinase.

  3. Drug

    Colestipol

    go.drugbank.com/drugs/DB00375
    Approved

    , patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut. … [FDA Label, F4555, F4567, L6262] The resultant lack of systemic exposure consequently means the medication generally demonstrates very few adverse effects inside the body.

  4. Drug

    Rasagiline

    go.drugbank.com/drugs/DB01367
    ApprovedInvestigational

    Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Oxtriphylline

    go.drugbank.com/drugs/DB01303
    Approved

    Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. … Its main physiological reponse is to dilate the bronchioles. As such, oxytriphylline is indicated mainly for asthma, bronchospasm, and COPD (i.e. all the same indications as the other theophyllines).

    Synonyms: Teofilinato de colina, Theophyllinate de choline
  6. Drug

    Tilactase

    go.drugbank.com/drugs/DB13761
    ApprovedInvestigational

    It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal. … [A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338]

  7. Drug

    Efavirenz

    go.drugbank.com/drugs/DB00625
    ApprovedInvestigational

    Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with … For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.

    Mixtures: TENOLAM-E, EFAVIRENZ, EMTRICITABINA E TENOFOVIR DISOPROXIL EGCategories: Antivirals used in combination for the treatment of HIV infections
  8. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    [L1118] It was never approved by the FDA.

    Categories: Sex Hormones and Modulators of the Genital System
  9. Drug

    Zileuton

    go.drugbank.com/drugs/DB00744
    ApprovedWithdrawn

    Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market. … These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients.

    Categories: Agents to Treat Airway Disease
  10. Drug

    Elafibranor

    go.drugbank.com/drugs/DB05187
    ApprovedInvestigational

    Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis. … [L50773] The drug was also approved by the EMA on September 23, 2024.[L51878]

    Synonyms: PROPANOIC ACID, 2-(2,6-DIMETHYL-4-((1E)-3-(4-(METHYLTHIO)PHENYL)-3-OXO-1-PROPEN-1-YL)PHENOXY)-Categories: Peroxisome Proliferator-activated Receptor Agonist